vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and Aterian, Inc. (ATER). Click either name above to swap in a different company.

Aterian, Inc. is the larger business by last-quarter revenue ($15.1M vs $13.5M, roughly 1.1× Assertio Holdings, Inc.). On growth, Aterian, Inc. posted the faster year-over-year revenue change (-38.5% vs -57.9%). Over the past eight quarters, Aterian, Inc.'s revenue compounded faster (-13.5% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Aterian, Inc. is a technology-enabled consumer products company that leverages artificial intelligence and data analytics to identify market demand, develop, source and distribute a wide portfolio of affordable goods spanning home improvement, wellness, personal care, pet supplies and outdoor recreation. It primarily sells its products through leading global e-commerce platforms, with core markets covering North America and Europe.

ASRT vs ATER — Head-to-Head

Bigger by revenue
ATER
ATER
1.1× larger
ATER
$15.1M
$13.5M
ASRT
Growing faster (revenue YoY)
ATER
ATER
+19.4% gap
ATER
-38.5%
-57.9%
ASRT
Faster 2-yr revenue CAGR
ATER
ATER
Annualised
ATER
-13.5%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
ATER
ATER
Revenue
$13.5M
$15.1M
Net Profit
$-7.9M
Gross Margin
56.1%
Operating Margin
-86.7%
-51.1%
Net Margin
-52.5%
Revenue YoY
-57.9%
-38.5%
Net Profit YoY
-512.2%
EPS (diluted)
$-4.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
ATER
ATER
Q4 25
$13.5M
$15.1M
Q3 25
$49.5M
$19.0M
Q2 25
$29.2M
$19.5M
Q1 25
$26.5M
$15.4M
Q4 24
$32.2M
$24.6M
Q3 24
$29.2M
$26.2M
Q2 24
$31.1M
$28.0M
Q1 24
$32.4M
$20.2M
Net Profit
ASRT
ASRT
ATER
ATER
Q4 25
$-7.9M
Q3 25
$11.4M
$-2.3M
Q2 25
$-16.4M
$-4.9M
Q1 25
$-13.5M
$-3.9M
Q4 24
$-1.3M
Q3 24
$-2.9M
$-1.8M
Q2 24
$-3.7M
$-3.6M
Q1 24
$-4.5M
$-5.2M
Gross Margin
ASRT
ASRT
ATER
ATER
Q4 25
56.1%
Q3 25
56.1%
Q2 25
54.3%
Q1 25
61.4%
Q4 24
63.4%
Q3 24
60.3%
Q2 24
60.4%
Q1 24
65.1%
Operating Margin
ASRT
ASRT
ATER
ATER
Q4 25
-86.7%
-51.1%
Q3 25
23.2%
-10.7%
Q2 25
-27.5%
-23.1%
Q1 25
-50.0%
-24.1%
Q4 24
-41.9%
-6.5%
Q3 24
-10.4%
-6.6%
Q2 24
-11.6%
-11.5%
Q1 24
-13.4%
-26.1%
Net Margin
ASRT
ASRT
ATER
ATER
Q4 25
-52.5%
Q3 25
23.1%
-12.0%
Q2 25
-56.0%
-25.0%
Q1 25
-51.1%
-25.4%
Q4 24
-5.3%
Q3 24
-10.0%
-6.8%
Q2 24
-11.8%
-13.0%
Q1 24
-13.9%
-25.5%
EPS (diluted)
ASRT
ASRT
ATER
ATER
Q4 25
$-4.54
Q3 25
$0.11
Q2 25
$-0.17
Q1 25
$-0.14
Q4 24
$-3.28
Q3 24
$-0.03
Q2 24
$-0.04
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
ATER
ATER
Cash + ST InvestmentsLiquidity on hand
$63.4M
$4.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$15.2M
Total Assets
$267.0M
$29.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
ATER
ATER
Q4 25
$63.4M
$4.9M
Q3 25
$93.4M
$7.6M
Q2 25
$98.2M
$10.5M
Q1 25
$87.3M
$14.3M
Q4 24
$100.1M
$18.0M
Q3 24
$88.6M
$16.1M
Q2 24
$88.4M
$20.3M
Q1 24
$80.7M
$17.5M
Total Debt
ASRT
ASRT
ATER
ATER
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
ATER
ATER
Q4 25
$94.0M
$15.2M
Q3 25
$105.8M
$22.6M
Q2 25
$93.3M
$24.3M
Q1 25
$108.5M
$27.0M
Q4 24
$121.1M
$30.0M
Q3 24
$130.5M
$30.6M
Q2 24
$132.2M
$30.9M
Q1 24
$134.5M
$33.0M
Total Assets
ASRT
ASRT
ATER
ATER
Q4 25
$267.0M
$29.6M
Q3 25
$319.8M
$40.1M
Q2 25
$273.8M
$45.4M
Q1 25
$286.4M
$49.8M
Q4 24
$284.7M
$49.5M
Q3 24
$276.0M
$52.1M
Q2 24
$279.4M
$59.9M
Q1 24
$282.0M
$55.7M
Debt / Equity
ASRT
ASRT
ATER
ATER
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
ATER
ATER
Operating Cash FlowLast quarter
$-30.0M
$-1.0M
Free Cash FlowOCF − Capex
$-1.0M
FCF MarginFCF / Revenue
-6.9%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
ATER
ATER
Q4 25
$-30.0M
$-1.0M
Q3 25
$-4.8M
$-1.6M
Q2 25
$19.1M
$-4.4M
Q1 25
$-12.5M
$-3.9M
Q4 24
$11.5M
$-9.0K
Q3 24
$-35.0K
$-722.0K
Q2 24
$7.4M
$2.9M
Q1 24
$7.5M
$-6.0K
Free Cash Flow
ASRT
ASRT
ATER
ATER
Q4 25
$-1.0M
Q3 25
$-1.6M
Q2 25
$-4.4M
Q1 25
Q4 24
Q3 24
Q2 24
$2.9M
Q1 24
$-42.0K
FCF Margin
ASRT
ASRT
ATER
ATER
Q4 25
-6.9%
Q3 25
-8.4%
Q2 25
-22.7%
Q1 25
Q4 24
Q3 24
Q2 24
10.3%
Q1 24
-0.2%
Capex Intensity
ASRT
ASRT
ATER
ATER
Q4 25
0.0%
Q3 25
0.2%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.0%
Q3 24
0.0%
0.0%
Q2 24
0.0%
Q1 24
0.2%
Cash Conversion
ASRT
ASRT
ATER
ATER
Q4 25
Q3 25
-0.42×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

ATER
ATER

Sales Channel Directly To Consumer$13.1M87%
Heating Cooling And Air Quality$2.1M14%

Related Comparisons